Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2022

セクキヌマブに関連する毒性シグナル: FDA有害事象報告システムに基づいたファーマコビジランス

Br J Clin Pharmacol. 2022 doi: 10.1111/bcp.15535

Zheng Y,

Guo X,

Chen C,

Chi L,

Guo Z,

Liang J,

Wei L,

Chen X,

Ye X,

He J

This study explored the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab with hypersensitivity identified as the most common toxicity.

Keywords:

JAK阻害薬失敗後: 次のJAK阻害薬か変更か –それが問題だ JAK-pot collaboration レジストリ

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835

Inanc N,

Leeb BF,

Rotar Z,

Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

Keywords:

September 2022

付着部炎関連または若年性乾癬性関節炎におけるセクキヌマブ: 無作為化, 二重盲検, プラセボ対照, 治療休薬, フェーズ3試験

Ann Rheum Dis. 2022 2022 2022-222849

Ayaz NA,

Ozen S,

Scott C,

Zhu X,

Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.

Keywords:

April 2022

オーラルサーベイランス試験とJAK阻害薬の安全性: 相対的な評価

Nat Rev Rheumatol. 2022. Epub ahead of print doi: 10.1038/s41584-022-00767-7

Winthrop KL,

Cohen SB.

Putting the data into context, Winthrop, et al. conclude that the ORAL Surveillance data are not dissimilar to those from the original developmental programme, which suggested additional safety concerns at the 10 mg dosage and that resulted in the 5 mg twice daily dosage as the approved dose for RA.Following the recent results of the ORAL Surveillance (ORALSURV) study, and the consequent changes to the utilisation of JAKinibs, made by the regulatory authorities, Winthrop, et al. aim to put the O...